Equities analysts expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to post $286.77 million in sales for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Integra LifeSciences Holdings Corporation’s earnings. The highest sales estimate is $288.80 million and the lowest is $284.60 million. Integra LifeSciences Holdings Corporation reported sales of $250.33 million during the same quarter last year, which would suggest a positive year over year growth rate of 14.6%. The business is expected to report its next quarterly earnings results on Thursday, October 26th.

According to Zacks, analysts expect that Integra LifeSciences Holdings Corporation will report full year sales of $286.77 million for the current fiscal year, with estimates ranging from $1.12 billion to $1.20 billion. For the next fiscal year, analysts anticipate that the company will post sales of $1.31 billion per share, with estimates ranging from $1.19 billion to $1.55 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting the consensus estimate of $0.45. The company had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.40 earnings per share.

Several brokerages recently weighed in on IART. UBS AG reiterated a “buy” rating and issued a $60.00 price target (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a report on Friday, June 9th. Oppenheimer Holdings, Inc. set a $60.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a report on Saturday, June 24th. Cantor Fitzgerald started coverage on Integra LifeSciences Holdings Corporation in a research report on Thursday, June 29th. They issued an “overweight” rating and a $65.00 price objective on the stock. Zacks Investment Research upgraded Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Raymond James Financial, Inc. upped their price objective on Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $54.45.

Integra LifeSciences Holdings Corporation (IART) traded down 0.15% during midday trading on Thursday, hitting $51.69. 26,409 shares of the stock traded hands. The stock has a market capitalization of $4.04 billion, a P/E ratio of 63.04 and a beta of 0.71. The stock’s 50-day moving average price is $50.60 and its 200-day moving average price is $49.08. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/05/analysts-expect-integra-lifesciences-holdings-corporation-iart-will-post-quarterly-sales-of-286-77-million.html.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. bought 10,000 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were purchased at an average price of $49.25 per share, for a total transaction of $492,500.00. Following the transaction, the director now directly owns 29,612 shares of the company’s stock, valued at approximately $1,458,391. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Donald E. Morel, Jr. bought 2,500 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $49.29 per share, for a total transaction of $123,225.00. Following the transaction, the director now directly owns 29,612 shares in the company, valued at $1,459,575.48. The disclosure for this purchase can be found here. Insiders have bought a total of 17,550 shares of company stock worth $864,842 in the last quarter. Insiders own 21.50% of the company’s stock.

Several large investors have recently made changes to their positions in IART. Strs Ohio lifted its position in shares of Integra LifeSciences Holdings Corporation by 100.0% during the 1st quarter. Strs Ohio now owns 4,800 shares of the life sciences company’s stock valued at $202,000 after buying an additional 2,400 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Integra LifeSciences Holdings Corporation by 100.0% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 28,532 shares of the life sciences company’s stock valued at $1,202,000 after buying an additional 14,266 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Integra LifeSciences Holdings Corporation by 106.7% during the 1st quarter. First Trust Advisors LP now owns 36,438 shares of the life sciences company’s stock valued at $1,535,000 after buying an additional 18,810 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Integra LifeSciences Holdings Corporation by 36.7% during the 1st quarter. Bank of New York Mellon Corp now owns 772,248 shares of the life sciences company’s stock valued at $32,536,000 after buying an additional 207,234 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Integra LifeSciences Holdings Corporation by 223.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after buying an additional 1,751 shares in the last quarter. Hedge funds and other institutional investors own 84.90% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.